Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis

Bruton's Tyrosine Kinase Inhibitors for Multiple Sclerosis Explained by NeurologistПодробнее

MS Research: BTK-inhibitor #shortsПодробнее

Fernando Dangond, AAN 2019 – Phase II study of first oral BTK inhibitor in multiple sclerosisПодробнее

Failed Clinical Trial for BTK inhibitor?! WTH?!Подробнее

The Future of Multiple Sclerosis TherapyПодробнее

BTK inhibitors for MS treatment: what do the recent trial readouts mean for the field?Подробнее

Xavier Montalban, EAN 2019 – Phase II study of first oral BTK inhibitor in multiple sclerosisПодробнее

BTK Inhibitors for MS: Progress in the Development of an Emerging Therapeutic ApproachПодробнее

BTK Inhibition and the Future of MS ManagementПодробнее

Potential of BTK Inhibitors for Primary Progressive Multiple SclerosisПодробнее

The safety and efficacy of evobrutinib in multiple sclerosisПодробнее

Updates on BTK inhibitor safety in multiple sclerosisПодробнее

Exploring the Rationale, Results, and Real-World Clinical Potential of BTKi in the Management of MSПодробнее

BTK Inhibitor - MS Trial #shortsПодробнее

The Road Ahead for BTK Inhibitors in Multiple SclerosisПодробнее

Fernando Dangond, MD, MBA: Evobrutinib for Relapsing Multiple SclerosisПодробнее

Innovations and Imaging in MS: Examining the Evidence, Looking Toward the Future of BTK InhibitorsПодробнее

Rationale, Evidence, and Practical Potential for BTK Inhibitors in Patient-Centered MS CareПодробнее

Investigating evobrutinib and other BTK inhibitors for the treatment of MSПодробнее

Xavier Montalban, EAN 2020 – Long-term Phase II Outcomes of First Oral BTK Inhibitor in MSПодробнее